In a groundbreaking international effort led by Dr. Shady Rahayel of Université de Montréal and reported by MSN.com, researchers have discovered new ways to predict which individuals with isolated REM sleep behavior disorder (iRBD) will go on to develop Parkinson’s disease or dementia with Lewy bodies (DLB). These findings mark a major stride toward precision medicine for neurodegenerative conditions.
iRBD: More Than Restless Sleep
iRBD is a sleep disorder where individuals physically act out their dreams—sometimes so vigorously that they or their bed partners are injured. Far from being a benign disturbance, iRBD is now recognized as a potent early warning sign of neurological decline. An estimated 90% of people with iRBD will eventually develop Parkinson’s or DLB, but until now, predicting which disease—or when it would arise—remained elusive.
Biomarker Breakthrough for Parkinson’s
The first study, published in Neurology and led by doctoral student Violette Ayral, followed 428 participants across five countries. By using an advanced MRI technique (DTI-ALPS), the team measured how efficiently the brain’s glymphatic system—responsible for clearing waste—was functioning. The study’s pivotal finding: iRBD patients with lower glymphatic activity on the brain’s left side were 2.4 times more likely to develop Parkinson’s disease. This asymmetry mirrors early Parkinson’s, where symptoms often begin on one side of the body. The research provides the first MRI-based evidence that impaired glymphatic function can serve as an early biomarker for Parkinson’s in people with iRBD.
A New Predictor for Dementia with Lewy Bodies
A companion study, led by doctoral student Celine Haddad and published in Alzheimer’s & Dementia, examined 438 participants to find a distinct marker for DLB. Researchers measured the amount of “free water” in the basal nucleus of Meynert, a brain region vital for cognition. Elevated free water levels, indicating early microscopic damage, predicted the development of DLB up to eight times more accurately than traditional measures. Importantly, this biomarker detects changes before symptoms even begin, offering a window for much earlier intervention.
Toward Personalized Prevention
These two complementary studies represent the largest international imaging research efforts involving iRBD patients. Their findings enable clinicians to distinguish, years in advance, which form of neurodegenerative disease a patient with iRBD is likely to develop. This opens the door to truly personalized monitoring, earlier interventions, and better-targeted clinical trials for preventive treatments.
“We already knew iRBD is a warning sign,” said Dr. Rahayel. “What we didn’t know was who would develop what. Thanks to these studies, we now have tools to better predict and personalize care.”
The work of Dr. Rahayel’s team offers hope that, with continued research and clinical application, neurodegenerative diseases like Parkinson’s and DLB can be detected and managed before irreversible damage sets in—potentially transforming the future of neurological care.
